124-48-1

Applied Filters:

Keyword:'124-48-1'

Showing 31-36 of 36 results for "124-48-1" within Papers

Validation of T-Track® CMV to assess the functionality of cytomegalovirus-reactive cell-mediated immunity in hemodialysis patients.

Bernhard Banas et al.

BMC immunology, 18(1), 15-15 (2017-03-09)

Uncontrolled cytomegalovirus (CMV) replication in immunocompromised solid-organ transplant recipients is a clinically relevant issue and an indication of impaired CMV-specific cell-mediated immunity (CMI). Primary aim of this study was to assess the suitability of the immune monitoring tool T-Track® CMV

Safety aspects of treatment with lacidipine--a slow-onset, long-acting calcium antagonist.

L H Lindholm et al.

Blood pressure, 5(4), 241-249 (1996-07-01)

The aim was to review the clinical safety profile of lacidipine with the help of the rather comprehensive datafile of the manufacturer- a novel approach which may be of some value while awaiting the outcome of calcium antagonist treatment in

Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial.

Roger D James et al.

The Lancet. Oncology, 14(6), 516-524 (2013-04-13)

Chemoradiation became the standard of care for anal cancer after the ACT I trial. However, only two-thirds of patients achieved local control, with 5-year survival of 50%; therefore, better treatments are needed. We investigated whether replacing mitomycin with cisplatin in

Digital fibromyxoma (superficial acral fibromyxoma): a detailed characterization of 124 cases.

Travis J Hollmann et al.

The American journal of surgical pathology, 36(6), 789-798 (2012-03-01)

Digital fibromyxoma (first described by Fetsch and colleagues as superficial acral fibromyxoma) is a distinctive soft tissue tumor with a predilection for the subungual or periungual region of the hands and feet. This report details the histologic, immunophenotypic, and clinical

Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial.

Jennifer G Robinson et al.

JAMA, 311(18), 1870-1882 (2014-05-16)

In phase 2 studies, evolocumab, a fully human monoclonal antibody to PCSK9, reduced LDL-C levels in patients receiving statin therapy. To evaluate the efficacy and tolerability of evolocumab when used in combination with a moderate- vs high-intensity statin. Phase 3

Cardiorespiratory biomarker responses in healthy young adults to drastic air quality changes surrounding the 2008 Beijing Olympics.

Junfeng Zhang et al.

Research report (Health Effects Institute), (174)(174), 5-174 (2013-05-08)

Associations between air pollution and cardiorespiratory mortality and morbidity have been well established, but data to support biologic mechanisms underlying these associations are limited. We designed this study to examine several prominently hypothesized mechanisms by assessing Beijing residents' biologic responses

Page 2 of 2